{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:31:38Z","timestamp":1790015498147,"version":"4.0.1"},"reference-count":76,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2021,9,2]]},"DOI":"10.1080\/13543784.2021.1955103","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T07:08:35Z","timestamp":1626160115000},"page":"965-973","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":27,"title":["Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options"],"prefix":"10.1080","volume":"30","author":[{"given":"Baptiste","family":"Le Calvez","sequence":"first","affiliation":[{"name":"Department of Hematology, Centre Hospitalier Universitaire, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"Department of Hematology, Centre Hospitalier Universitaire, Nantes, France"},{"name":"CRCINA, INSERM, CNRS, Universit\u00e9 d\u2019Angers, Universit\u00e9 de Nantes, France"},{"name":"Site de Recherche Int\u00e9gr\u00e9e sur le Cancer (SIRIC) \u00ab ILIAD \u00bb, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[{"name":"Department of Hematology, Centre Hospitalier Universitaire, Nantes, France"},{"name":"CRCINA, INSERM, CNRS, Universit\u00e9 d\u2019Angers, Universit\u00e9 de Nantes, France"},{"name":"Site de Recherche Int\u00e9gr\u00e9e sur le Cancer (SIRIC) \u00ab ILIAD \u00bb, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1038\/35074122"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(94)90071-X"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80089-8"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.2.459"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1126\/science.1202947"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090847"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271874"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0267"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31821ca6ce"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051482"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.213"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5682"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.03.011"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0200"},{"issue":"3","key":"cit0021","first-page":"e41","volume":"186","author":"*Ribrag V","year":"2019","journal-title":"Br J Haematol"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-632919"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000300"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0055"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.04.005"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15234"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15946"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-775122"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30110-3"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30109-7"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0148"},{"key":"cit0033","unstructured":"Research C for DE and. FDA alerts healthcare professionals and oncology clinical investigators about two clinical trials on hold evaluating keytruda\u00ae (pembrolizumab) in patients with multiple myeloma. FDA [Internet]; 2019 [cited 2021 Jan 3]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-alerts-healthcare-professionals-and-oncology-clinical-investigators-about-two-clinical-trials."},{"key":"cit0034","author":"Moreau P","journal-title":"BJH"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32956-3"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.23693"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123713"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124339"},{"key":"cit0041","author":"Cohen YC","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102452"},{"key":"cit0043","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer [internet]. httpdxdoiorgpasserelleuniv-rennes1fr101056NEJMoa1200690. Massachusetts Medical Society; 2012 [cited 2021 Jan 30]. Available from: https:\/\/www-nejm-org.passerelle.univ-rennes1.fr\/doi\/10.1056\/NEJMoa1200690."},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383"},{"issue":"35","key":"cit0045","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","author":"Postow MA","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1038\/s41424-018-0049-9"},{"key":"cit0047","first-page":"173","volume":"4","author":"Barroso-Sousa R","year":"2018","journal-title":"Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol"},{"key":"cit0048","unstructured":"Nishino M, Sholl LM, Hatabu H, et al. Anti\u2013PD-1\u2013related pneumonitis during cancer immunotherapy [Internet]. Httpsdoi-Orgpasserelleuniv-Rennes1fr101056NEJMc1505197. Massachusetts Medical Society; 2015 [cited 2021 Jan 30]. Available from: https:\/\/www-nejm-org.passerelle.univ-rennes1.fr\/doi\/10.1056\/NEJMc1505197."},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1803602"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0069"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.015"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1038\/nature14292"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202005"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-825265"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-864231"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.08.009"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.584530"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98888"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910340314"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0219"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438028"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.117531"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3073"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0105"},{"key":"cit0066","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma [Internet]. Httpsdoi-Orgpasserelleuniv-Rennes1fr101056nejmoa1504030. Massachusetts Medical Society; 2015 [cited 2021 Mar 2]. Available from: https:\/\/www-nejm-org.passerelle.univ-rennes1.fr\/doi\/10.1056\/NEJMoa1504030."},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14169"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0458"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112572"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1457"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30756-7"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2021.1955103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T18:07:53Z","timestamp":1631383673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2021.1955103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,2]]}},"alternative-id":["10.1080\/13543784.2021.1955103"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2021.1955103","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}